Emerson Strengthens Leadership in Life Sciences Industry with Acquisition of Fluxa

Rhea-AI Summary

Emerson (NYSE: EMR) has announced the acquisition of Fluxa, enhancing its software and technology portfolio in the life sciences sector. This strategic move aims to accelerate the delivery of new therapies, drugs, and vaccines. The acquisition of Fluxa’s PKM™ software, integrated with Emerson’s DeltaV™ control system, is expected to streamline drug development, improving speed and operational integrity. This initiative caters to the growing demand for rapid market introduction of biopharmaceuticals, a need amplified by the COVID-19 pandemic.

Positive

• Acquisition of Fluxa enhances Emerson's software capabilities.
• Fluxa's PKM™ software integration is expected to improve drug development speed.
• Supports Emerson's positioning in the growing life sciences market.

Negative

• None.

Acquisition complements Emerson’s software and technology portfolio and helps accelerate delivery of life-saving medicines

ST. LOUIS--(BUSINESS WIRE)-- Emerson (NYSE: EMR) today announced it has acquired Fluxa, a leader in the life sciences industry that uses software and modern technology architectures to accelerate the speed to market for new therapies, drugs and vaccines. The acquisition builds on Emerson’s leading software and solutions portfolio and life sciences expertise. Emerson made an equity investment in Fluxa, which is based in Glendale, California, in 2021.

Fluxa accelerates the speed to market for new therapies by helping drug development and manufacturing organizations harness the power of collaboration and data across sites, functions and processes. The acquisition of Fluxa’s PKM™ software will provide customers a unique solution, integrated with Emerson’s industry leading DeltaV™ control system and life sciences automation software, accelerating the development of new drug therapies into production.

“The life sciences industry has grown rapidly, and speed to market has become increasingly important since the emergence of COVID-19,” said Mark Bulanda, Executive President of Emerson Automation Solutions. “Emerson’s automation solutions and market leadership, combined with Fluxa’s software, automates technology transfer in one step, giving bio-pharmaceutical companies unprecedented agility to get therapies safely to patients during this critical time.”

By translating and transferring the scientific processes and workflows into the automation language of manufacturing operational technology (OT) facilities, Emerson can help digitize the drug development process, enabling speed, flexibility and multi-product manufacturing, and improved operational integrity.

About Emerson

Emerson (NYSE: EMR), headquartered in St. Louis, Missouri (USA), is a global technology and software company providing innovative solutions for customers in industrial, commercial and residential markets. Our Automation Solutions business helps process, hybrid and discrete manufacturers maximize production, protect personnel and the environment while optimizing their energy and operating costs. Our Commercial & Residential Solutions business helps ensure human comfort and health, protect food quality and safety, advance energy efficiency and create sustainable infrastructure. For more information visit Emerson.com.

Forward-Looking and Cautionary Statements

Statements in this press release that are not strictly historical may be “forward-looking” statements, which involve risks and uncertainties, and Emerson undertakes no obligation to update any such statements to reflect later developments. These risks and uncertainties include the scope, duration and ultimate impact of the COVID-19 pandemic and the Russia-Ukraine conflict, as well as economic and currency conditions, market demand, including related to the pandemic and oil and gas price declines and volatility, pricing, protection of intellectual property, cybersecurity, tariffs, competitive and technological factors, among others, as set forth in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220630005661/en/

For Emerson

Investor Contact: Colleen Mettler 314-553-2197

Media Contact: Charlotte Boyd 952-994-8607

Source: Emerson

FAQ

What is the significance of Emerson's acquisition of Fluxa?

The acquisition enhances Emerson's software capabilities in the life sciences sector, helping to accelerate the delivery of new therapies.

How will the acquisition of Fluxa impact Emerson's stock?

The acquisition could strengthen Emerson's market position and revenue potential in the life sciences, which may positively influence its stock performance.

What technology is Emerson acquiring with Fluxa?

Emerson is acquiring Fluxa's PKM™ software, which is designed to streamline drug development processes.

When was the acquisition of Fluxa announced?

The acquisition was announced today, furthering Emerson's commitment to enhancing its life sciences solutions.